Repros Therapeutics

Repros Therapeutics — Investor Presentation (November 2007)

46 slides from Repros Therapeutics's investor presentation, Nov 5, 2007

  1. Slide 1: Developing clinical stage small molecule therapeutics for hormonal and reproductive disorders

    Slide 1: Developing clinical stage small molecule therapeutics for hormonal and reproductive disorders

    Developing clinical stage small molecule therapeutics to treat hormonal and reproductive system disorders

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements and information regarding the future performance and actions of Repros Therapeutics Inc. (RPRX) that involve risks and uncertainties that could cause actual results and actions to differ materially. These risks include

  3. Slide 3: Repros Strategy

    Slide 3: Repros Strategy

    Repros Strategy Focus on small molecule therapeutics for reproductive system disorders that exhibit significant market potential and that are currently underserved Develop highly differentiable drugs Proellex for the treatment of uterine fibroids and endometriosis Androxal for the treatment of endoc

  4. Slide 4: a r—“—i—~—~—~——C

    Slide 4: a r—“—i—~—~—~——C

    a r—“—i—~—~—~——C — —rt—‘O™ONN—r—h Ah, _ : S 2 c ee es _ i - - oe ae a . 2 _ 2 atts — Z A <2 rk cy i Seen Ln _ — _ . ae ee LLL

  5. Slide 5: Proellex Product Development Timeline

    Slide 5: Proellex Product Development Timeline

    Proellex Product Development Timeline H1'04 H2'04 H1'05 H2'05 H1'06 H2'06 H1'07 H2'07 H1'08 H2'08 H1'09 H2'09 H1'10 H2'10 Cummulative Spending Euro PHI/II UF PreClin Tox US PH II/III UF Study. US UF Extension Study Carcinogenicity Studies US PH III Anemia Euro Endo Phase II US Endo Phase II US PH II

  6. Slide 6: Proellex Overview

    Slide 6: Proellex Overview

    Proellex Overview New class of selective progesterone receptor modulator (SPRM) No antiglucocorticoid activity Potential indications: uterine fibroids, endometriosis, breast cancer and HRT Potential significant advantages over existing GnRHa therapies No loss of bone mineral density in clinical tria

  7. Slide 7: How Proellex Works

    Slide 7: How Proellex Works

    How Proellex Works Blocks hypothalamus / pituitary axis Shuts down hormonal secretions Long-term side effects including bone loss Selectively blocks progesterone activity Allows tonic hormone secretions Alleviates negative side effects of GnRHa Potential for chronic use GnRHa Proellex Hypothalamus P

  8. Slide 8: Uterine Fibroids

    Slide 8: Uterine Fibroids

    Uterine Fibroids Benign, monoclonal, hormone sensitive, smooth muscle tumors of the uterus Most common tumor of the female reproductive tract Heavy bleeding / anemia Abdominal pressure / pain / urinary frequency Affect 20-77% of women age 35 - 55 600,000 hysterectomies conducted annually annually an

  9. Slide 9: European Phase I/II

    Slide 9: European Phase I/II

    European Phase I/II 12 weeks Placebo 94 12.5 mg Proellex 61 25 mg Proellex 45 50 mg Proellex 47 Lupron 54 Asoprisnil 25mg 64 0 0.5 1 2 3 4 6 8 12 16 24 12.5 mg 91 512 417 199 171 171 153 139 101 79 193 25 mg 374 620 1184 759 593 570 532 501 401 347 333 50 mg 209 760 1355 681 465 371 364 294 238 205

  10. Slide 10: Phase 2/3 Uterine Fibroid Trial

    Slide 10: Phase 2/3 Uterine Fibroid Trial

    Phase 2/3 Uterine Fibroid Trial Final Top-Line Data Released April 3, 2007 Design: N=150 Women with signs and symptoms of uterine fibroids Doses of 0mg, 12.5mg, 25mg Proellex Treated for 3 month with 1 year open label extension Up to 20 US clinical sites Status: 127 patients enrolled, 96 completed,

  11. Slide 11: ZPU-003 Uterine Fibroid Study - Pictoral Blood Loss

    Slide 11: ZPU-003 Uterine Fibroid Study - Pictoral Blood Loss

    ZPU-003 Uterine Fibroid Study - Pictoral Blood Loss BL Mo 1 Mo 2 Mo 3 Placebo 113.5 91 83 69 Proellex 12.5 mg 133.5 1 1 1 Proellex 25 mg 120 1 1 1 Median PBAC Score 12.5 and 25 mg p < 0.0001 vs Pl Menorrhagia

  12. Slide 12: ZPU-003 Uterine Fibroid Study - Hemoglobin

    Slide 12: ZPU-003 Uterine Fibroid Study - Hemoglobin

    ZPU-003 Uterine Fibroid Study - Hemoglobin <11.5 g/DL BL Mo 1 Mo 2 Mo 3 Placebo 10.6 10.6 10.5 10.2 Proellex 12.5 mg 10.2 10.3 12 12.4 Proellex 25 mg 9.9 10.8 11.9 12.1 Median Hemoglobin g/DL 12.5 and 25 mg p < 0.002 vs Pl 1 g increase = ~1 pint of blood

  13. Slide 13: Phase 2/3 Uterine Fibroid Trial UFSQOL

    Slide 13: Phase 2/3 Uterine Fibroid Trial UFSQOL

    Phase 2/3 Uterine Fibroid Trial UFSQOL Symptom Severity Concern Placebo 40.1 61.6 12.5 mg Proellex 17.4 83.6 25 mg Proellex 14.9 86.6 Normal 22.5 84 UFSQOL Uterine Fibroid Symptom Survey p vs placebo < 0.0001 for both doses p vs placebo < 0.005 for both doses Spies et al, Obstetrics & Gynecology, vo

  14. Slide 14: Phase 2/3 Uterine Fibroid Trial Safety Conclusions

    Slide 14: Phase 2/3 Uterine Fibroid Trial Safety Conclusions

    Phase 2/3 Uterine Fibroid Trial Safety Conclusions Most common drug related side effects Amenorrhea: 78.6% (no longer considered a side effect) Hot Flashes: 16.7% With a small data base, differences in low incidence events have to be interpreted with caution No tendency toward endometrial hyperplasi

  15. Slide 15: Summary of FDA Meetings Held to Date for Proellex

    Slide 15: Summary of FDA Meetings Held to Date for Proellex

    Summary of FDA Meetings Held to Date for Proellex FDA willing to consider development of drug for several uterine fibroid indications Preoperative treatment Treatment of perimenopausal women with fibroids Chronic treatment of fibroids to avoid surgery Repros plans to commence a double-blind, placebo

  16. Slide 16: Endometriosis

    Slide 16: Endometriosis

    Definition: the presence of epithelial and stromal endometrial cells outside of the uterine cavity Complaints of infertility or pregnancy loss Pelvic pain/back pain Dyspareunia (pain during sex) Dysmenorrhea (menstrual cycle cramps) Endometriosis 5% of women of reproductive age Estimated that 25 - 4

  17. Slide 17: Phase 1/2 Endometriosis Trial Updated Interim Analysis

    Slide 17: Phase 1/2 Endometriosis Trial Updated Interim Analysis

    Phase 1/2 Endometriosis Trial Updated Interim Analysis Fewer mean days of pain with 50mg Proellex (higher percentage of pain free days than with Lupron) p< 0.05 Lupron not statistically different than 12.5mg and 25mg Proellex dose % Pain Free Days As Reported thru Month 6

  18. Slide 18: Endometrial Thickening/Hyperplasia?

    Slide 18: Endometrial Thickening/Hyperplasia?

    Endometrial Thickening/Hyperplasia? Dosing on Day 5

  19. Slide 19: Proellex Effects on Endometrial Thickness

    Slide 19: Proellex Effects on Endometrial Thickness

    Proellex Effects on Endometrial Thickness Month 3 12.5mg 9 25mg 4 Placebo 6 US Phase II/III Study 0 3 6 Lupron 5.3 3.1 3.5 12.5mg 9.8 11.8 20.9 25mg 8.9 12.9 16.6 50mg 11 9.2 14.5 FDA Recommended Thickness Cutoff Statistically Significant Difference In Month 6 Thicknesses

  20. Slide 20: Unopposed estrogen effect vs Proellex

    Slide 20: Unopposed estrogen effect vs Proellex

    Unopposed estrogen effect vs Proellex Proliferative Disordered Proliferative Benign Endometrial Hyperplasia Estrogen over Time cysts remodeling variable density Mutter et al, 2007 12.5mg Proellex

  21. Slide 21: Proellex Effects on Estradiol

    Slide 21: Proellex Effects on Estradiol

    Proellex Effects on Estradiol Baseline Month 3 Lupron 154 16.7 12.5 mg Proellex 117 48.8 25 mg Proellex 93.8 75.8 50 mg Proellex 117 46.5 Lupron Produces Statistically Significant Drop in E2 p=0.0007 No Statistically Significant Changes for Proellex Doses Estradiol Baseline vs Month 3

  22. Slide 22: Proellex Effects on Markers of Bone Resorption and Formation

    Slide 22: Proellex Effects on Markers of Bone Resorption and Formation

    Proellex Effects on Markers of Bone Resorption and Formation Baseline Month 3 Lupron 0.39 0.53 12.5 mg Proellex 0.26 0.36 25 mg Proellex 0.29 0.31 50 mg Proellex 0.29 0.33 ratio @ baseline ratio @ 3 Months 12.5mg 47.9 38 25mg 39.7 36 Placebo 39.1 34 N-Teliopeptide/Creatinine Ratio Bone Resorption Ma

  23. Slide 23: Proellex Regulatory Strategy

    Slide 23: Proellex Regulatory Strategy

    Proellex Regulatory Strategy (Pending Nov. 30, 2007 Type B FDA Meeting) Pursue short course treatment of anemia Pursue chronic symptomatic relief of fibroids Pursue chronic symptomatic relief of endometriosis Small pivotal Phase III's due to strong effect signal in all indications (25 patients per a

  24. Slide 24: a r—“—i—~—~—~——C

    Slide 24: a r—“—i—~—~—~——C

    a r—“—i—~—~—~——C — —rt—‘O™ONN—r—h Ah, _ : S 2 c ee es _ i - - oe ae a . 2 _ 2 - - - e | 7 sili e e ae aS ee - ' -— oo - - - - - - - ue _ | a ge ee q —rr—“—™— ee ae oe a . a ae ee LLL

  25. Slide 25: Androxal

    Slide 25: Androxal

    Androxal Trans isomer of clomiphene citrate Cis isomer opposes action and has increased side effect risk Antiestrogen that normalizes pituitary responsiveness in 2^ hypogonadal men Highly statistically significant results in 6 month Phase III study showing restoration of pituitary responsiveness res

  26. Slide 26: Testosterone Market

    Slide 26: Testosterone Market

    Testosterone Market 6/04-6/05 US 461 Rest of World 140 2004 Figures 2003 2004 2005 est. Total Market 399 459 486 Androgel 275 308 326 Androderm 50 57 55 Testim 13 31 43 Testosterone Inj. 31 31 24 A U.S. Phenomenon

  27. Slide 27: Androxal Phase III Trial

    Slide 27: Androxal Phase III Trial

    Androxal Phase 3 Trial Enrollment completed in Nov. '06 N = 194 men at 18 US sites Patient testosterone levels < 300 ^g/dl FDA agreement re: safety not efficacy Randomized into 4 arms: 2 doses of Androxal, placebo, and Androgel 6 mo study with efficacy assessment at 3 mo with roll over to 12 mo open

  28. Slide 28: Androxal Type C FDA Meeting Outcome

    Slide 28: Androxal Type C FDA Meeting Outcome

    Androxal Type C FDA Meeting: Oct. 15,2007 Outcome The Bad Testosterone level is an insufficient primary endpoint for Phase III studies of non-testosterone treatments No known quality of life endpoints are sufficient as primary endpoints Avoidance of side effects of testosterone therapy unacceptable

  29. Slide 29: 0.5 Androgel Androgel 0 470 373 435 351 401 Androgel 651 761 798 776

    Slide 29: 0.5 Androgel Androgel 0 470 373 435 351 401 Androgel 651 761 798 776

    0 0.5 1 2 12 24 Androgel 192 325 457 523 523 635 Androgel 270 470 373 435 351 401 Androgel 651 761 798 776 1036 1036 Androgel 1163 1221 1046 1321 1293 1113 Androgel 568 1016 1268 1493 2552 1183 50 mg 347 389 470 419 402 482 50 mg 768 770 883 720 626 1104 50 mg 709 634 747 742 819 793 50 mg 607 663 7

  30. Slide 30: Advantages of Androxal Over Leading Therapies

    Slide 30: Advantages of Androxal Over Leading Therapies

    Advantages of Androxal Over Leading Therapies Androxal No Partner Risk Self Limiting Dose No Abuse No Supra-Normal Levels Simple Treatment & Follow- up More Reproducible Results Maintain/Restore Fertility Oral Therapy Restoration of Normal Function Potential for Non-Chronic Therapy T Gels/Creams & I

  31. Slide 31: ZA-003 Androxal Adverse Events by System Organ Class

    Slide 31: ZA-003 Androxal Adverse Events by System Organ Class

    ZA-003 Androxal - Hypogonadotrophic Hypogonadism Adverse Events by System Organ Class Organ Class Androxal 12.5mg Androxal 25mg Androgel Placebo Respiratory 15.9 8.0 10.6 10.6 GI 13.6 8.0 4.3 8.5 General 11.4 6.0 4.3 2.1 Investigations 6.8 6.0 17.0 2.1 Musc Skel 13.6 0 8.5 12.8 Cardiac 2.3 8.0 2.1 2

  32. Slide 32: Androxal Regulatory Strategy

    Slide 32: Androxal Regulatory Strategy

    Androxal Regulatory Strategy Conduct Phase IIb study in men with AIHH and Metabolic Syndrome Conduct Phase IIb study in hypogonadal men of reproductive age showing improvement or maintenance of fertility/sperm status No primary Quality of Life endpoints

  33. Slide 33: Impact of Hypogonadism on Insulin Sensitivity and Metabolic Syndrome

    Slide 33: Impact of Hypogonadism on Insulin Sensitivity and Metabolic Syndrome

    Impact of Hypogonadism on Insulin Sensitivity and Metabolic Syndrome T<280 T>280 East 4.3 7.4 American Heart Association definition of Metabolic Syndrome Elevated waist circumference, ^ 40" Triglycerides, ^ 150 mg/dl Reduced HDL, < 40 mg/dl Elevated Blood Pressure, ^ 130/85 Elevated Fasting Glucose,

  34. Slide 34: Endocrine Effects of Androxal US Phase III Safety Study Results

    Slide 34: Endocrine Effects of Androxal US Phase III Safety Study Results

    Endocrine Effects of Androxal US Phase III Safety Study Results 0 1 2 3 12.5 263 210 201 219 25 184 189 167 159 Androgel 199 181 198 196 Placebo 204 203 202 202 0 1 2 3 12.5 120.7 118 111.5 109.7 25 120.8 119 111.6 111.4 Androgel 108.9 106.6 106.5 113.2 Placebo 114 115 114.7 117.4 0 1 2 3 12.5 204 1

  35. Slide 35: Androxal Lasting Pituitary Stimulation

    Slide 35: Androxal Lasting Pituitary Stimulation

    Androxal Lasting Pituitary Stimulation Screening 12:00:00 AM 1/10/1900 1/14/1900 1/21/1900 26 33 99 50mg 258.5 306.4 602.8 607.4 579.6 563 535 300 25mg 253.1 295.8 476.8 546.1 456.1 405 300 300 12.5mg 225.1 216 484.4 436.6 356.9 300 300 300 5G Androgel 244 278.8 384 534.6 281 Placebo 267.9 305.1 253

  36. Slide 36: Change in Serum Glucose

    Slide 36: Change in Serum Glucose

    Change in Serum Glucose Subset of Men BMI>26, Glucose >99 (+50% patients studied) 0 1 2 3 Androxal Pooled 0 -15 -16 -23 No significant change in Placebo or Androgel arms Significant mean change in Androxal arm p<0.01 0 1 2 3

  37. Slide 37: Metabolic Syndrome Clinical Strategy

    Slide 37: Metabolic Syndrome Clinical Strategy

    Metabolic Syndrome Clinical Strategy Submit white paper to FDA FDA to determine if IND to be moved to endocrine division Commence Phase IIb study in academic setting to elucidate Androxal effects on metabolic syndrome Submit protocol for Phase III study once Phase IIb is complete

  38. Slide 38: Impact of Androxal on Male Fertility

    Slide 38: Impact of Androxal on Male Fertility

    Impact of Androxal on Male Fertility Baseline 6 Months Androgel 5.42 1.1 12.5 mg Androxal 7.02 9.1 25 mg Androxal 6.4 11.8 Comparison of Means p=0.011 Comparison of Median p=0.0045 32% of men in study under age of 50 Exogenous testosterone suppresses pituitary secretion of FSH FSH required for stimu

  39. Slide 39: Fertility Clinical Strategy

    Slide 39: Fertility Clinical Strategy

    Fertility Clinical Strategy Submit white paper to FDA Commence Phase IIb study in academic setting to elucidate Androxal effects on fertility Submit protocol for Phase III study once Phase IIb is complete

  40. Slide 40: Androxal Product Development Timeline

    Slide 40: Androxal Product Development Timeline

    Androxal Product Development Timeline H1'04 H2'04 H1'05 H2'05 H1'06 H2'06 H1'07 H2'07 H1'08 H2'08 H1'09 H2'09 H1'10 H2'10 Cummulative Spending US PHI/II PreClin Tox US PH III Safety Study. US Extension Study Carcinogenicity Studies US PH Ib Fertility US PH IIb metabolism Phase III Studies End of PII

  41. Slide 41: Repros Fundamentals

    Slide 41: Repros Fundamentals

    Repros Fundamentals Shares Outstanding 12,774,904 (all common, no warrants) 2005 Cash Burn $7,391,000 2006 Cash Burn $14,195,000 (no debt) Estimated Burn 2007 <$18,000,000 Unaudited Cash on 10/24/07 : approximately $27.8million Estimated Cash Yearend 2007: +$20 million

  42. Slide 42: Repros Ownership

    Slide 42: Repros Ownership

    Repros Ownership Filing on 10-27-06 Total Reporting Shares: 5,993,082 HBK Management LLC 943,400 ProMed Management LLC 843,485 Great Point Partners LLC 721,100 Xmark Opportunity Partners LLC 698,739 Efficacy Capital Ltd 672,528 UBS Securities LLC 628,801 Quogue 605,754 Caxton Associates LLC 177,505

  43. Slide 43: Date Close Volume 10/24/2007 0.075796 10/23/2007 0.2111 10/22/2007 0.0761 10/19/2007 0.099 10/18/2007 0.1058 10/17/2007

    Slide 43: Date Close Volume 10/24/2007 0.075796 10/23/2007 0.2111 10/22/2007 0.0761 10/19/2007 0.099 10/18/2007 0.1058 10/17/2007

    Date Close Volume 10/24/2007 0.075796 10/23/2007 0.2111 10/22/2007 0.0761 10/19/2007 0.099 10/18/2007 0.1058 10/17/2007 0.2012 10/16/2007 0.5684 10/15/2007 0.0367 10/12/2007 0.061 10/11/2007 0.1115 10/10/2007 0.0286 10/9/2007 0.0544 10/8/2007 0.0259 10/5/2007 0.0911 10/4/2007 0.0907 10/3/2007 0.1284

  44. Slide 44: Anticipated Financing Events

    Slide 44: Anticipated Financing Events

    Anticipated Financing Events Attempt to License Ex-US Androxal Opportunity If no license, raise +$20 million mid Q2 Funding post Ph II Proellex data and second cycle fibroid results If license of Androxal +$10 million, fund raising delayed until Q3 If Market Cap stagnates attempt Japan license for P

  45. Slide 45: Recent and Upcoming Milestones

    Slide 45: Recent and Upcoming Milestones

    Recent and Upcoming Milestones ? 4Q06 Report interim U.S. Phase 3 Androxal results ? 4Q06 Report interim results from Proellex Phase 1/2 endometriosis trial ? 4Q06 Report interim results from Proellex Phase 2/3 fibroid trial ? 1Q07 Raise $33 million in public offering ? 2Q07 Report top-line Proellex

  46. Slide 46: a r—“—i—~—~—~——C

    Slide 46: a r—“—i—~—~—~——C

    a r—“—i—~—~—~——C — —rt—‘O™ONN—r—h ac _ _ oe GQ () oon ' - oe ns ~ iS D> aw acl Vata ee a S S a a a a .DLhmLDrDrrrrr—“‘“‘“‘“*“CR;SCSC*C C—O rt—é=t—‘“‘—CSs‘<Ssé‘—‘—‘i”siézi”sisi;s;< <;C;«3©3723C~73;3Z~CSZzCSZzCZ;C3C=C3C~;3SECS:és -

Source: SEC EDGAR · 8-K filed Nov 5, 2007

More decks from Repros Therapeutics